Search

Search Constraints

You searched for: Author/Creator Habermann, Thomas M.

Search Results

1. A multicentre study of primary breast diffuse large B‐cell lymphoma in the rituximab era. (27th January 2014)

2. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy. Issue 5 (22nd March 2017)

3. A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. Issue 9 (2nd September 2018)

4. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma. Issue 7 (12th June 2013)

5. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). Issue 4 (7th July 2015)

6. A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. (9th September 2016)

7. Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma – tissue remains the issue. Issue 10 (3rd October 2017)

8. Acute coronary syndromes in patients with active hematologic malignancies – Incidence, management, and outcomes. (15th January 2019)

9. Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. Issue 12 (20th April 2021)

10. Analysis and impact of a multidisciplinary lymphoma virtual tumor board. Issue 14 (5th December 2020)